SCHEMBL26808422

SCHEMBL26808422

Cn1cc(S(=O)(=O)Nc2nc(Cl)c(C(F)(F)F)c(Cl)n2)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KAT6A Q92794 1/20 0.39
▸ KAT5 Q92993 1/20 0.39
▸ CCNE1 P24864 4/20 0.35
▸ CDK2 P24941 4/20 0.35
▸ CCNT1 O60563 3/20 0.35
▸ CDK1 P06493 3/20 0.35
▸ CCNB1 P14635 3/20 0.35
▸ CDK9 P50750 3/20 0.35
▸ CDK4 P11802 1/20 0.35
▸ CCND1 P24385 1/20 0.35
▸ CCND3 P30281 1/20 0.35
▸ CDK7 P50613 1/20 0.35
▸ CCNH P51946 1/20 0.35
▸ MNAT1 P51948 1/20 0.35
▸ CDK6 Q00534 1/20 0.35
▸ NLRP3 Q96P20 1/20 0.35
▸ OXTR P30559 1/20 0.34
▸ AVPR1A P37288 1/20 0.34
▸ CCNE2 O96020 3/20 0.34
▸ EGFR P00533 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309609 0.91 KAT6A (0.39) KAT6AKAT5CCNE1CDK2CCNT1
SCHEMBL24309540 0.90 KAT6A (0.38) KAT6AKAT5CCNE1CDK2CCNT1
SCHEMBL24309573 0.88 HTR1A (0.38) KAT6AKAT5CCNE1CDK2CCNT1
SCHEMBL24309976 0.88 MALT1 (0.35) KAT6AKAT5CCNE1CDK2CCNT1
SCHEMBL24309831 0.85 KAT6A (0.41) KAT6AKAT5CCNE1CDK2CCNT1
SCHEMBL24309813 0.85 NLRP3 (0.38) KAT6AKAT5CCNE1CDK2CCNT1
SCHEMBL29566415 0.84 AURKA (0.37) EGFRFGFR1KDRMALT1ALDH1A1
SCHEMBL24309366 0.84 PDE10A (0.38) KAT6AKAT5CCNE1CDK2CCNT1
SCHEMBL29566971 0.83 HTR1A (0.37) KAT6AKAT5CDK1HTR1AHTR7
SCHEMBL24310058 0.83 GAA (0.38) KAT6AKAT5CCNE1CDK2CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B KAT6A 2853/4885KAT5 3390/4885CCNE1 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback